Aurobindo Receives FDA Approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg
Published: January 21, 2026
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg. Aurobindo Pharma’s Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Ziac Tablets manufactured by Teva Branded Pharmaceutical Products R&D LLC.
Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, are indicated in the:
- Management of hypertension